title: Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer.
abstract: OBJECTIVE
  To evaluate the efficacy of omeprazole plus clarithromycin and furazolidone in Helicobacter pylori eradication and duodenal ulcer healing in Brazilian patients.
  
  
  METHODS
  Forty H. pylori-positive patients with duodenal ulcer were randomized to receive 20 mg omeprazole o.m. or b.d. for 1 month plus 500 mg clarithromycin (b.d. ) and 200 mg furazolidone (b.d.) for 1 week.
  
  
  RESULTS
  Three months after the end of the treatment the eradication rates were 90% by intention-to-treat analysis, and 97% by per protocol analysis. Mild side-effects were observed in 25 patients, none of whom abandoned the protocol. No difference was observed between the 20 mg and 40 mg omeprazole daily doses. Cure or significant improvement of the symptoms and of the histological alterations were observed after H. pylori eradication.
  
  
  CONCLUSIONS
  Our results demonstrate that clarithromycin and furazolidone in combination with omeprazole are a good alternative for H. pylori eradication in Brazilian patients with duodenal ulcer.
authors.affiliation: Department of Pathology of the School of Medicine of the Federal University of Minas Gerais, Belo Horizonte, Brazil. dani@unix.horizontes.com.br
authors.forename: R
authors.initials: R
authors.lastname: Dani
authors.forename: D M
authors.initials: DM
authors.lastname: Queiroz
authors.forename: M G
authors.initials: MG
authors.lastname: Dias
authors.forename: J M
authors.initials: JM
authors.lastname: Franco
authors.forename: L C
authors.initials: LC
authors.lastname: Magalhães
authors.forename: G S
authors.initials: GS
authors.lastname: Mendes
authors.forename: L S
authors.initials: LS
authors.lastname: Moreira
authors.forename: L P
authors.initials: LP
authors.lastname: De Castro
authors.forename: N H
authors.initials: NH
authors.lastname: Toppa
authors.forename: G A
authors.initials: GA
authors.lastname: Rocha
authors.forename: M M
authors.initials: MM
authors.lastname: Cabral
authors.forename: P G
authors.initials: PG
authors.lastname: Salles
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects; D001938:Brazil; D017291:Clarithromycin / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000473:pathology; D004724:Endoscopy; D005260:Female; D005664:Furazolidone / Q000008:administration & dosage* / Q000009:adverse effects; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage* / Q000009:adverse effects; D011897:Random Allocation; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D005664:Furazolidone; D017291:Clarithromycin; D009853:Omeprazole